You are here

  • Home
  • Archive
  • Volume 75, Issue 4
  • Evaluation of the association between anticarbamylated protein antibodies and the longitudinal course of functional ability in rheumatoid arthritis

Article Text

Article menu

Download PDFPDF

Electronic pages
Correspondence
Evaluation of the association between anticarbamylated protein antibodies and the longitudinal course of functional ability in rheumatoid arthritis
Free
  1. S Ajeganova1,2,
  2. B Svensson3,
  3. T W J Huizinga2,
  4. A H M van der Helm-van Mil2,
  5. H W van Steenbergen2
  1. 1Rheumatology Unit, Department of Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
  2. 2Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  3. 3Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden
  1. Correspondence to Dr Sofia Ajeganova, Rheumatology Unit R92, Department of Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm 14186, Sweden; sofia.ajeganova{at}ki.se

https://doi.org/10.1136/annrheumdis-2015-208954

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Clinically relevant joint destruction has now become infrequent in patients with newly diagnosed rheumatoid arthritis (RA), while other disease outcomes such as functional ability and disease persistence have become more important. Recently, novel auto-antibody reactivities have been identified in RA, with the ultimate aim to better characterise patients with RA. Anticarbamylated protein (anti-CarP) antibodies were recently identified and associated with more severe radiographic progression,1 but the association with other outcomes was unexplored. With great interest we read the study by Humphreys et al,2 reporting more severe functional disability in anti-CarP positive patients with inflammatory polyarthritis. According to the reported unadjusted β-coefficient (95% CI), patients with anti-CarP antibodies had 0.21 (0.14 to 0.29) higher scores on the Health Assessment Questionnaire (HAQ) during a median follow-up duration of 8 years. This association was statistically independent of the presence of anticitrullinated peptide antibodies (ACPA) and rheumatoid factor (RF). In general replication …

    View Full Text

    Linked Articles